CAGE Bio Inc.

Quick facts

Phase 2 pipeline

• CGB-400
  CGB-400 is designed to target and inhibit a specific pathway involved in disease progression, though the exact mechanism is not publicly disclosed.
• CGB-400 Topical Gel
• CGB-500 Ointment with 1% tofacitinib · Immunology
  Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.
• CGB-500 with 0.5% tofacitinib
  Combination therapy incorporating tofacitinib, a JAK inhibitor, with CGB-500, whose mechanism remains undisclosed.
• Ruxolitinib 1.5% Cream QD

Phase 1 pipeline

• CGB-S-100
• Drug: CGB-600 gel, experimental drug

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CAGE Bio Inc. portfolio CI brief
• CAGE Bio Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies